Roche Secures CE Mark for Elecsys NfL Blood Test to Monitor Multiple Sclerosis

Basel, Switzerland — In a move that could fundamentally shift how clinicians monitor neuroinflammatory activity, Roche announced on April 13, 2026, that its Elecsys® Neurofilament Light Chain (NfL) test has received CE mark approval. The test is specifically designed to detect neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis (RRMS).

For those of us who track the intersection of health, longevity, and high-performance living here at Archysport, this development represents a significant leap in diagnostic accessibility. By utilizing a minimally invasive blood sample, the Elecsys NfL test offers a streamlined alternative to some of the more cumbersome standard-of-care methods currently used to track disease progression.

A Shift in Monitoring: From MRI to Blood Samples

Managing multiple sclerosis requires constant vigilance. For clinicians, the goal is to detect changes in a patient’s condition as quickly as possible to optimize treatment and intervene early. Historically, this has relied heavily on routine clinical assessments and MRI scanning.

However, MRI access is not universal. Many patients face significant hurdles in obtaining regular scans, which can delay the detection of new neuroinflammatory activity. The Elecsys NfL blood test addresses this gap by providing a different type of insight—measuring biological markers of neuroaxonal damage that reflect the underlying inflammation.

This does not replace the MRI but rather complements it. By combining the structural data of a scan with the biological data of a blood test, medical professionals can gain a more comprehensive picture of a patient’s status.

Understanding NfL and Neuroaxonal Damage

To understand why this test matters, it is necessary to gaze at what the test is actually measuring. NfL, or Neurofilament Light Chain, is a protein that is released into the bloodstream when nerve cells are injured. When neuroinflammation occurs in patients with RRMS, it leads to neuroaxonal damage, triggering the release of this protein.

By quantifying the levels of NfL in a simple blood sample, the Elecsys NfL test provides a biological window into the damage being caused by the disease. This allows doctors to monitor the “biological damage” of multiple sclerosis more regularly than was previously practical for the average patient.

Note for our readers: In medical terms, “minimally invasive” refers to procedures that require a small incision or, in this case, a simple needle draw, rather than more intensive imaging or invasive biopsies.

Scaling Access for Millions

The scale of the necessitate is immense. Multiple sclerosis is a chronic condition affecting more than 2.9 million people worldwide. For a population of this size, the ability to move monitoring from specialized imaging centers to local clinics is a game-changer.

Due to the fact that the test requires only a blood sample, collections can be handled locally. This reduces the travel burden on patients and allows for more frequent check-ins, which is critical for the timely adjustment of therapies.

Technical Standardization via Cobas

One of the primary challenges with biological markers is consistency—results can vary wildly between different labs or different equipment. Roche has addressed this by designing the Elecsys NfL test to be performed on its widely available cobas instruments.

Using a standardized platform ensures that results remain consistent and reliable regardless of where the test is conducted. This standardization is vital for clinicians who need to track a patient’s NfL levels over months or years to determine if a specific treatment is working or if the disease is accelerating.

As Editor-in-Chief, I’ve seen how diagnostic breakthroughs can change the trajectory of recovery and management in professional sports. While this specific test targets a chronic neurological condition, the move toward “liquid biopsies”—using blood to detect internal damage—is a trend that will likely ripple across all areas of sports medicine and neurology.

The next confirmed step for this technology will be its integration into clinical workflows across Europe following the CE mark approval. We will continue to monitor official updates from Roche regarding the rollout of the test to healthcare providers.

What are your thoughts on the shift toward blood-based monitoring for neurological health? Let us know in the comments below.